



The Economics of Drug Therapy: Access and Affordability Issues

Louis Andrew*

Department of Pharmacology, University of Groningen, Groningen, The Netherlands

*Corresponding Author: Louis Andrew, Department of Pharmacology, University of Groningen, Groningen, The Netherlands; E-mail: louis_a@yahoo.com

Received date: 21 July, 2024, Manuscript No. JPSED-24-148315;

Editor assigned date: 23 July, 2024, PreQC No. JPSED -24-148315 (PQ);

Reviewed date: 06 August, 2024, QC No. JPSED -24-148315;

Revised date: 13 August, 2024, Manuscript No. JPSED-24-148315 (R);

Published date: 20 August, 2024, DOI: 10.4172/2380-9477.1000201.

Description

The economics of drug therapy is a major area of concern, encompassing the costs associated with drug development, pricing and the resulting access and affordability for patients. As the global healthcare landscape evolves, the disparity between the availability of life-saving medications and the financial capacity of patients to access these treatments continues to be a pressing issue. Drug therapy, which plays a pivotal role in the management and cure of diseases, is often hindered by cost barriers, leading to widespread health inequities [1-3]. This essay explores the economic factors that influence drug pricing, the challenges of access and affordability and potential solutions to improve patient outcomes. One of the key economic drivers of high drug prices is the immense cost associated with drug development. These costs stem from extensive research, clinical trials, regulatory approval processes and post-market surveillance.

The patent system further complicates the issue of affordability. Patents grant pharmaceutical companies exclusive rights to market their drugs for a period of 20 years, allowing them to set prices without competition. While this period is intended to help companies recoup their investment, it often results in prices that are unaffordable for many patients, especially in Low- And Middle-Income Countries (LMICs). When patents expire, generic drug manufacturers can enter the market, offering the same medications at a fraction of the price. However, the lag between the introduction of new drugs and the availability of generics can be substantial, limiting access for those in immediate need [4-7].

The rising cost of drug therapy has created a significant barrier to access, particularly for patients with chronic illnesses or those requiring long-term treatments. In many cases, the high cost of medications forces patients to make difficult choices between affording essential drugs or meeting other basic needs such as food and housing. This issue is particularly acute in the United States of America, where healthcare costs, including prescription medications, are among the highest in the world. According to a 2022 report by the Commonwealth Fund, approximately one-third of Americans have skipped filling a prescription due to cost concerns.

Moreover, the disparity in drug pricing between countries further exacerbates access issues. In high-income countries, public and private insurance schemes often cover a significant portion of drug costs, making medications more accessible. However, in LMICs, out-of-

pocket expenditures for drugs can constitute a significant portion of household income, leading to treatment non-adherence and poor health outcomes. Even in countries with universal healthcare systems, such as Canada or the UK, certain innovative or high-cost medications may not be covered under public drug plans, leaving patients with limited options. Addressing the economics of drug therapy requires a multifaceted approach [8-10]. One potential solution is the implementation of price controls and transparency measures to prevent excessive drug pricing. Countries like Germany and Japan have instituted pricing caps and negotiations with pharmaceutical companies to limit the cost of medications.

In the United States of America, there is growing support for allowing Medicare to negotiate drug prices directly with pharmaceutical companies, a move that could potentially lower costs for millions of patients. The economics of drug therapy presents a complex challenge, where the high cost of drug development and the resulting pricing strategies create significant barriers to access and affordability. For many patients, especially in low-income settings, these economic hurdles can mean the difference between life and death. However, through a combination of policy reforms, increased availability of generics and global partnerships, the affordability and accessibility of essential drug therapies can be improved. By addressing these economic issues, the global health community can move closer to ensuring equitable access to life-saving medications for all.

References

1. Buzaglo JS, Charap ES, House L, Gupta NK, Longacre M. (2016) Definitions of value among patients with breast cancer.
2. Dunfee TW. (2006) Do firms with unique competencies for rescuing victims of human catastrophes have special obligations? Corporate responsibility and the AIDS catastrophe in Sub-Saharan Africa. *J Bus Ethics* 16(2):185-210.
3. Tarazi W, Finegold K, Sheingold S, De Lew N, Sommers BD. (2022) Prescription Drug Affordability among Medicare Beneficiaries. *ASPE*.
4. Mulcahy A, Whaley C, Tebeka M, Schwarn D, Edemfield N, et al. (2021) International prescription drug price comparisons. Santa Monica: RAND Corporation.
5. Aballéa S, François C, Fricke FU, Malone D, Millier A, et al. (2020) Health economic evaluation of gene replacement therapies: Methodological issues and recommendations. *J Mark Access Health Policy* 8(1):1822666.
6. Chambers JD, Panzer AD, Kim DD, Margaretos NM, Neumann PJ. (2019) Variation in US private health plans' coverage of orphan drugs. *Am J Manag Care*. 25(10):508-512.
7. Garrison LP, Kleinermans D. (2022) Is the world ready for gene therapy?. *Haemophilia* 28:5-8.
8. Haendel M, Vasilevsky N, Groza T, McMurry J, Dawkins H, et al. (2020) How many rare diseases are there? *Nat Rev Drug Discov* 19(2):77-78.
9. Lakdawalla DN, Phelps CE. (2020) Health technology assessment with risk aversion in health. *J Health Econ* 72:102346.
10. Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, et al. (2022) The national economic burden of rare disease in the United States in 2019. *Orphanet J Rare Dis*. 17(1):163.

Citation: Andrew L (2024) *The Economics of Drug Therapy: Access and Affordability Issues*. *J Pharm Sci Emerg Drugs* 12:4.